Lamotrigine (LTG) is an antiepileptic drug that is metabolized via glucuronidation. Since the glucuronidizing enzyme is inducible by estrogens, LTG serum concentrations may fall by 50-60% when combined with hormonal contraceptives that contain ethinyl estradiol (EE). Little is known about a possible interaction between estrogens used for hormone replacement therapy (HRT) and LTG, and the few available data are conflicting. Data from serum samples analyzed for LTG were therefore retrieved from a routine therapeutic drug monitoring database. Users of HRT and EE were identified and matched with controls for age and dose. No enzyme-inducing or enzyme-inhibiting comedication was allowed. LTG serum concentration-todose ratios (CDRs) were calculated. Case groups and their respective control groups were compared by the Mann-Whitney U test. Seventy-nine HRT users (dose range 1-4 mg/day) and 200 EE users (dose range 20-40 lg/day), as well as 158 and 400 matching controls, respectively, could be included. Both EE users and HRT users had significantly lower mean LTG CDRs than their respective matched controls. These results suggest that HRT with estrogens may reduce serum LTG concentrations.
Lamotrigine (LTG) is one of the most used antiepileptic drugs (AEDs), especially in women. It is metabolized mainly via glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) 1A4. Because UGT1A4 is inducible by estrogens, 1 LTG serum concentrations often fall by 50-60% when combined with hormonal contraceptives that contain ethinyl estradiol. This drug interaction is well documented. [2] [3] [4] LTG serum concentrations may also fall by >50% during pregnancy, and this fall correlates with the serum estradiol concentration. [5] [6] [7] Hormone replacement therapy (HRT) with estrogen is common in postmenopausal women. Lifetime prevalences of HRT use of 20.8-48% have been reported. [8] [9] [10] It has also been reported that 50-71% of HRT-treated women with epilepsy may experience an increase in seizure frequency. 11 Because estrogens are generally categorized as pro-convulsant agents, 12 the reported worsening in seizure activity may be a direct estrogen effect, but it may also be due to a drug interaction leading to lower serum concentrations of antiepileptic medications that are metabolized via glucuronidation.
The possibility of such a drug interaction between estrogens used for HRT and LTG has not been investigated systematically. A PubMed search identified only four relevant studies, and they produced conflicting results. Increased, unchanged, and reduced LTG clearance was found in postmenopausal women. 11, [13] [14] [15] Moreover, only one of these studies specifically addressed HRT.
The present study therefore aimed at exploring the possibility of a drug interaction between LTG and estrogens used for HRT.
Methods

Patient selection
This study used historical datasets from the routine therapeutic drug monitoring (TDM) database of the St. Olav University Hospital Department of Clinical Pharmacology in Trondheim, Norway. All serum samples sent to the laboratory and analyzed for LTG in the period of October 1999 to May 2007 were initially selected.
Patient names were replaced by an electronically generated study ID. Information on gender and age was derived from each patient's population registry number. After calculation of the patient's age at the time of sampling, the population registry number was also deleted.
The following exclusion criteria were then applied:
• • Unclear, or lack of, essential information (e.g., daily LTG dose or time between last dose and blood sampling)
The remaining samples were then filtered for use of HRT with oral or transdermal preparations. These HRT users constituted the case group. Because the data used for this study were routine, with all their limitations (i.e., a certain proportion of samples with incorrect or incomplete information on dose, comedication, time since last intake), patients using hormonal contraception with ethinyl estradiol (EE) were included as case group 2, in order to validate the method. Patients using no estrogens at all served as the control population.
Each patient in the HRT group and in the EE group, respectively, was then matched age-and dose-wise with two randomly selected patients from the control population. The matching was done by the case-control-matching feature of SPSS 22 (IBM Corp., Armonk, NY, U.S.A.). This resulted in four groups: HRT users with a matched control group, and EE users with a matched control group. Cases where no matching control could be found were removed before further analysis.
In the study by Harden et al., 11 two patients on LTG experienced a decrease in their LTG serum concentration by 25-30% while taking conjugated equine estrogens/medroxyprogesterone acetate (MPA). A sample size calculation with mu1 (i.e., concentration-to-dose ratio [CDR] = 0.058 (control) and mu2 = 0.0435 (75% of mu1) resulted in a required minimum sample size of n = 30 (with standard deviation [SD] 0.02; a = 0.05; b = 0.2). Thus, to detect a possible reduction of the mean LTG CDR by 25%, at least 30 patients were needed per group.
Data analysis
Data handling was done using Microsoft Excel 2016 (Microsoft Corp., Redmond, WA, U.S.A.) and SPSS 22.0 (IBM Corp.). The LTG serum CDR was calculated by dividing the serum concentration by the total daily dose. Thus, the CDR represents the serum concentration per each milligram of LTG given.
Data are presented as mean AE SD unless otherwise stated. Normality testing revealed that the distribution of CDR values in all groups was right-skewed. The nonparametric Mann-Whitney U test was therefore used to compare the case groups to their respective control groups.
Figures were created with SPSS 22.0 and then converted to publication quality images with GIMP 2.8.14 (https:// www.gimp.org).
Results
The initial database consisted of 10.822 serum samples, of which 6.185 were from female patients. After application of the exclusion and filter criteria, 86 users of LTG plus HRT, as well as 212 users of LTG plus EE, remained. After case-control matching, 7 cases from the HRT group and 12 cases from the EE group had to be excluded due to lack of matching controls. Thus, 79 HRT cases and 200 EE cases were available for statistical analysis.
The daily hormone doses used by the HRT group were as follows: estradiol 1 mg (n = 1), estradiol sequential preparation 1-2 mg (n = 27), estradiol 2 mg (n = 12), estradiol 4 mg (n = 1), estradiol 1 mg + norethisterone 0.5 mg (n = 8), estradiol 2 mg + norethisterone 1 mg (n = 10), estradiol transdermal patch (dose not specified; n = 1), estradiol dose not specified (n = 7), estriol 1 mg (n = 2), estriol 2 mg (n = 7), and estriol 3 mg (n = 3). The daily doses used by the EE group were as follows: 20 lg (n = 3), 30 lg (n = 89), 35 lg (n = 37), 30 lg + 40 lg sequentially (n = 55), transdermal patch (n = 4), vaginal ring (n = 4), and not specified (n = 8). Further clinical characteristics of cases and controls as well as LTG serum concentrations and CDRs are summarized in Table 1 . As expected, EE use was associated with significantly lower LTG CDR (p < 0.001), which demonstrated that the method used was suitable to detect relevant differences between groups. Also in the HRT group, the mean LTG serum concentration as well as the CDR were significantly lower than in the control group (Table 1) .
The distribution of the CDR values is illustrated by Figure 1 .
Discussion
It has long been known that both exogenous and endogenous estrogens can induce UGT1A4, the major enzyme responsible for the metabolism of LTG. Thus, hormonal contraception with EE as well as pregnancy, which may give a several 100-fold rise of serum estrogens, may reduce LTG serum concentrations. Although these effects have been thoroughly investigated, 1-7 a possible effect of HRT on LTG kinetics has not been studied systematically.
To the author's knowledge, this is the first study specifically designed to explore the possibility of an interaction between HRT with estrogens and LTG. There are only four previous studies on the pharmacokinetics of LTG in postmenopausal women, and their results are conflicting. Moreover, only one of them specifically reported a possible interaction between HRT and LTG. In that study, the two patients that were using LTG had a 25-30% lower LTG serum concentrations after starting HRT, and one of them experienced an increase of her epileptic seizures. 11 The second of these previous studies found a higher LTG clearance in women of postmenopausal age, compared to younger women. However, the use of steroid hormones was an exclusion criterion.
14 By contrast, a third study from the same group as the second one, found no effect of postmenopausal age on LTG clearance. 15 Finally, the fourth study found a lower LTG clearance in women of postmenopausal age. 13 The results of these studies are difficult to interpret and to compare: studies 1 11 and 2 14 were small and prospective, whereas studies 3 15 and 4 13 were large historical database studies. Moreover, only the first of these studies 11 specifically addressed HRT. The second study excluded HRT users, 14 whereas the third and fourth study focused only on possible effects of postmenopausal age and did not control for use of HRT. 13, 15 The effect of HRT on LTG serum concentrations found in this study is difficult to explain. Although estrogens should be considered as potential inducers of UGT-enzymes, 1 HRT is not commonly known to cause drug interactions. Postmenopausal age itself has been associated with unaltered, increased, and reduced LTG clearance. [13] [14] [15] Given that HRT intends to restore serum estradiol concentrations to premenopausal levels, it would be expected that the LTG CDR of women receiving HRT does not differ from HRT controls or from premenopausal women. In postmenopausal women, estradiol levels are usually below 20 pg/ml. During treatment with 2 mg estradiol/day, the average peak serum level is 80 pg/ml at steady state. Such levels correspond to the lower end of the range found in premenopausal women. During the menstrual cycle, estradiol levels may rise up to 350 pg/ml in the preovulatory phase. 16 However, several studies have demonstrated that LTG levels remain stable during the menstrual cycle, suggesting that fluctuations of such magnitude do not affect LTG clearance. 14, 17, 18 Thus, further research is necessary to explain how HRT may reduce LTG serum concentrations. Many different forms of estrogens are used for HRT, including estradiol, estriol, and conjugated equine estrogens. This study was not designed to detect possible differences between the various forms of estrogens. In terms of pharmacologic potency, EE is in a class of its own. The potency of estrogens used for HRT is more difficult to compare, due to their complicated metabolism including conversion and reconversion into each other, and to the cascade of intracellular events generated by the activation of estrogen receptors. 16 Moreover, 85% of the HRT users in this study used estradiol, whereas only 15% used estriol. While this study suggests an effect of estradiol/ estriol on LTG serum levels, a previous study reported a similar effect of conjugated equine estrogens , although in only two patients. 11 Further studies are needed to examine possible differences between various forms of estrogen on LTG serum concentrations, and to describe potential doseeffect relationships.
In this study, it was not possible to validate the clinical information stated on the laboratory request form. Therefore, some of this information may have been incomplete or incorrect. Experience shows that the use of comedication including enzyme inducers or enzyme inhibitors sometimes is not stated. Sometimes the blood sample might not have been taken drug-fasting, despite being indicated as such. Examination of the outlier values and their respective medical records showed no association with LTG dose or with the EE or estrogen dose, supporting the hypothesis that these values most presumably were caused by drug intake shortly before blood sampling. Other blood samples may have been taken during pregnancy, or to control for suspected or known low treatment adherence. These factors may explain the relatively broad range of CDRs in each of the groups, as illustrated by Figure 1 . On the other hand, the fact that the range was broad in all groups suggests that such putatively incomplete or incorrect clinical information was equally prevalent in all groups.
In conclusion, the present study suggests that HRT with estrogens may reduce LTG serum concentrations. Because this was a historical study based on routine data, the results should be interpreted with caution. A prospective, crossover study would be desirable to further explore this possible drug interaction.
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